Three companies—AriBio Holdings, AriBio, and AriBio Lab—are joining forces as a “one team” under the AriBio Group to conquer degenerative brain diseases, including Alzheimer’s disease (dementia). They presented a “blueprint” for completing the full Jeonju bio value chain (value chain) spanning prevention, treatment, and management, and leaping forward as a global healthcare group.
The AriBio Group held a vision announcement event on the 1st at Seoul Dragon City in Yongsan-gu, Seoul, under the slogan “One Name One Vision,” presenting its core business strategies and growth roadmap.
Jeong Jae-jun (Chairman) stated, “Dementia begins 10 years before diagnosis, or even up to 20 years prior,” adding, “Until now, the pharmaceutical industry has focused primarily on treatment after diagnosis, leaving management during the pre- and post-diagnosis periods unaddressed.” He continued, “We have been considering an integrated solution that accounts for the Jeonju period of dementia in the last 30 years of life,” and added, “The AriBio Group will build prevention, treatment, and management into a single system.”
First, AriBio Lab is taking the lead in prevention. The company plans to extend its pipeline—including the shingles vaccine “CVI-VZV-001,” which has completed second-dose administration in Phase 2 clinical trials—and its immune-enhancing platform technologies, such as “L-pampo” and “Lipo-pam,” to dementia prevention. The goal is to secure top-line (key endpoint) data from the Phase 2 shingles trial in the first half of next year, followed by entry into Phase 3 trials and commercialization in 2029–2030, while simultaneously initiating a Phase 1/2a trial for an Alzheimer’s prevention vaccine.
Jeon Eun-young, Vice President of AriBio Lab, who presented the business strategy on the day, emphasized, “Research published in NATURE and other journals suggests that shingles vaccines addressing immune aging and inflammation can reduce dementia risk.” She added, “AriBio Lab is ‘prepared’ for developing dementia prevention technologies, equipped with platform expertise, clinical trial experience with the shingles vaccine, a workforce that is 70 percent or more graduate-degree holders, and patents.”
AriBio is responsible for the treatment field. Its core pipeline asset, “AR1001,” has completed a global Phase 3 clinical trial involving 1,535 early-stage Alzheimer’s disease patients across approximately 230 clinical trial institutional investors in 13 countries, including the United States, Europe, South Korea, and China. The top-line results are scheduled to be first presented at the Clinical Trials on Alzheimer’s Disease (CTAD 2026) conference, to be held in Boston, U.S., on November 16.
AriBio has completed the production of finished dosage forms for AR1001 regulatory approval and plans to utilize Contract Development and Manufacturing Organizations (CDMOs) in India and the United States for commercial drug supply. Following the release of global Phase 3 results, the company aims to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) next year and obtain approval the following year. It also plans to expand indications from dementia to stroke, Parkinson’s disease, and vascular dementia. Fred Kim, Vice President of AriBio, stated, “We will also consider introducing next-generation technologies,” adding, “Our goal is to achieve 1 trillion won in revenue by 2030 through upfront payments, milestones, and sales royalties.”
AriBio Holdings, which has accumulated business capabilities in the lighting and electrical sectors, will connect the group’s infrastructure and capital while managing post-treatment care. The company plans to strengthen its revenue base through high-value-added lighting and electrical businesses and expand into consumer healthcare by supplying AI (artificial intelligence) data infrastructure and selling “Herzion,” a vibration-based electronic drug for dementia.
Kim Hoi-cheon, Oh Hol-ding-seu (President) of AriBio, stated, “As a holding company, we will invest our own business profits into expanding equity stakes in subsidiaries, supporting R&D at AriBio Lab, and bio investments and mergers and acquisitions (M&A).” He added, “We will deliver results through increased equity value from the growth of portfolio companies and AI/data infrastructure supply by subsidiaries, thereby enhancing shareholder value for Holdings.” Regarding the recent collapse of the merger with AriBio, he said, “I am sorry to our shareholders,” adding, “We will ensure that AriBio’s entry into the capital market is definitely realized under the leadership of Holdings.”
Approximately 150 attendees, including key executives and employees, were present at the vision announcement event on the day. strikeout pharmaceutical Choi Ji-hyeon (CEO) and Kim Sang-jin (President) visited the site to encourage the group’s launch. Jeong (Chairman) emphasized, “Although AriBio Group consists of separate legal entities, it shares the vision of ‘a world where everyone can live as themselves until the very end.’” He added, “We will prove the group’s value through results and communicate accurately and swiftly.”
in THEBIO
